Do Wall Street Analysts Like Danaher Stock?

Company Overview - Danaher Corporation (DHR) is a Washington, D.C.-based company that designs, manufactures, and markets professional, medical, research, and industrial products and services, with a market capitalization of $153 billion [1] Stock Performance - DHR shares have underperformed the broader market over the past year, gaining only 8% compared to the S&P 500 Index's increase of nearly 14.4% [2] - Year-to-date (YTD) performance shows DHR stock down 4%, while the S&P 500 has risen by 1.4% [2] - Compared to the Robo Global Healthcare Technology and Innovation ETF (HTEC), which gained about 17.6% over the past year, DHR's performance is notably weaker [3] Financial Results - For Q4, DHR reported an adjusted EPS of $2.23, reflecting a 4% year-over-year increase, with revenue of $6.84 billion, exceeding Wall Street forecasts of $6.79 billion [5] - The company anticipates full-year adjusted EPS in the range of $8.35 to $8.50 [5] Analyst Expectations - Analysts project DHR's EPS to grow by 7.8% to $8.41 on a diluted basis for the current fiscal year ending in December [6] - DHR has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [6] - Among 23 analysts covering DHR, the consensus rating is a "Strong Buy," with 18 "Strong Buy" ratings, one "Moderate Buy," and four "Holds" [6] Price Targets - UBS analyst maintains a "Buy" rating on DHR with a price target of $270, indicating a potential upside of 22.9% from current levels [8] - The mean price target is $264.05, representing a 20.2% premium to current price levels, while the highest price target of $310 suggests an ambitious upside potential of 41.1% [8]